Obesity - Pipeline Review, H2 2013

Date: August 30, 2013
Pages: 541
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O5F2BC0D9C1EN
Leaflet:

Download PDF Leaflet

Obesity - Pipeline Review, H2 2013
Obesity - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Obesity - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Obesity.
  • A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Obesity.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Obesity Overview
Therapeutics Development
Obesity Therapeutics under Development by Companies
Obesity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Obesity Therapeutics - Products under Development by Companies
Obesity Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Obesity Therapeutics Development
Obesity - Therapeutics Assessment
Drug Profiles
Obesity Therapeutics - Drug Profile Updates
Obesity Therapeutics - Discontinued Products
Obesity Therapeutics - Dormant Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products Under Development for Obesity, H2 2013
Products under Development for Obesity - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Development by Companies, H2 2013 (Contd..2)
Number of Products under Development by Companies, H2 2013 (Contd..3)
Number of Products under Development by Companies, H2 2013 (Contd..4)
Number of Products under Development by Companies, H2 2013 (Contd..5)
Number of Products under Development by Companies, H2 2013 (Contd..6)
Number of Products under Development by Companies, H2 2013 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Development by Companies, H2 2013 (Contd..2)
Products under Development by Companies, H2 2013 (Contd..3)
Products under Development by Companies, H2 2013 (Contd..4)
Products under Development by Companies, H2 2013 (Contd..5)
Products under Development by Companies, H2 2013 (Contd..6)
Products under Development by Companies, H2 2013 (Contd..7)
Products under Development by Companies, H2 2013 (Contd..8)
Products under Development by Companies, H2 2013 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2013
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
Boehringer Ingelheim GmbH, H2 2013
Shionogi & Co., Ltd., H2 2013
Amgen Inc., H2 2013
Sanofi-Aventis, H2 2013
AstraZeneca PLC, H2 2013
Eli Lilly and Company, H2 2013
Athersys, Inc., H2 2013
GlaxoSmithKline plc, H2 2013
Isis Pharmaceuticals, Inc., H2 2013
Merck & Co., Inc., H2 2013
Novo Nordisk A/S, H2 2013
Takeda Pharmaceutical Company Limited, H2 2013
Plexxikon Inc., H2 2013
BioLineRx, Ltd., H2 2013
Ipsen S.A., H2 2013
Chong Kun Dang Pharmaceutical, H2 2013
Glenmark Pharmaceuticals Ltd., H2 2013
GTx, Inc., H2 2013
Kissei Pharmaceutical Co., Ltd., H2 2013
Mitsubishi Tanabe Pharma Corporation, H2 2013
Norgine Limited, H2 2013
Pfizer Inc., H2 2013
VIVUS, Inc., H2 2013
Zydus Cadila Healthcare Limited, H2 2013
Genfit, H2 2013
Arrowhead Research Corporation, H2 2013
Ligand Pharmaceuticals Incorporated, H2 2013
Calzada Limited, H2 2013
PROLOR Biotech, Inc., H2 2013
NeuroSearch A/S, H2 2013
Orchid Chemicals & Pharmaceuticals Ltd, H2 2013
Corcept Therapeutics Incorporated, H2 2013
Arena Pharmaceuticals, Inc., H2 2013
WhanIn Pharmaceutical Co., Ltd., H2 2013
Unigene Laboratories, Inc., H2 2013
Theratechnologies Inc., H2 2013
Bukwang Pharmaceutical Co., Ltd., H2 2013
LG Life Sciences, Ltd, H2 2013
Transition Therapeutics Inc., H2 2013
Suven Life Sciences Ltd., H2 2013
Phynova Group Ltd, H2 2013
Orexigen Therapeutics, Inc., H2 2013
DiaMedica Inc., H2 2013
NeuroVive Pharmaceutical AB, H2 2013
Digna Biotech, S.L., H2 2013
Betagenon AB, H2 2013
Sirtris Pharmaceuticals, Inc., H2 2013
Jenrin Discovery, Inc., H2 2013
Upsher-Smith Laboratories, Inc., H2 2013
Metabolex, Inc, H2 2013
Helsinn Healthcare S.A., H2 2013
Xenon Pharmaceuticals Inc., H2 2013
Spherix Incorporated, H2 2013
Ocera Therapeutics, Inc., H2 2013
Aileron Therapeutics, Inc., H2 2013
AngioChem Inc., H2 2013
Global Health Ventures Inc., H2 2013
Zafgen Inc., H2 2013
Ambrx, Inc., H2 2013
Braasch Biotech LLC, H2 2013
Zealand Pharma A/S, H2 2013
Indus Biotech Private Limited, H2 2013
Intarcia Therapeutics, Inc., H2 2013
Thrasos, Inc., H2 2013
Versartis, Inc., H2 2013
Kainos Medicine, Inc., H2 2013
Avaxia Biologics, Inc., H2 2013
Omeros Corporation, H2 2013
Aegis Therapeutics, LLC, H2 2013
BRIDGE BIORESEARCH PLC, H2 2013
Globeimmune, Inc., H2 2013
Targacept, Inc., H2 2013
Molecular Design International, Inc., H2 2013
N-Gene Research Laboratories, Inc., H2 2013
PepTcell Limited, H2 2013
Galenea Corp., H2 2013
Verva Pharmaceuticals Limited, H2 2013
Regulus Therapeutics Inc., H2 2013
Esperion Therapeutics, Inc., H2 2013
Domainex Ltd., H2 2013
Lithera, Inc., H2 2013
DiscoveryBiomed, Inc., H2 2013
GlaxoSmithKline Inc., H2 2013
Motif BioSciences, Inc., H2 2013
Sirona Biochem Corp, H2 2013
Vicore Pharma AB, H2 2013
Reviva Pharmaceuticals Inc., H2 2013
PharmaIN Corporation, H2 2013
Rhythm Pharmaceuticals, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Obesity Therapeutics - Drug Profile Updates
Obesity Therapeutics - Discontinued Products
Obesity Therapeutics - Discontinued Products (Contd..1)
Obesity Therapeutics - Discontinued Products (Contd..2)
Obesity Therapeutics - Discontinued Products (Contd..3)
Obesity Therapeutics - Discontinued Products (Contd..4)
Obesity Therapeutics - Discontinued Products (Contd..5)
Obesity Therapeutics - Dormant Products
Obesity Therapeutics - Dormant Products (Contd..1)
Obesity Therapeutics - Dormant Products (Contd..2)
Obesity Therapeutics - Dormant Products (Contd..3)
Obesity Therapeutics - Dormant Products (Contd..4)
Obesity Therapeutics - Dormant Products (Contd..5)
Obesity Therapeutics - Dormant Products (Contd..6)
Obesity Therapeutics - Dormant Products (Contd..7)
Obesity Therapeutics - Dormant Products (Contd..8)
Obesity Therapeutics - Dormant Products (Contd..9)
Obesity Therapeutics - Dormant Products (Contd..10)

LIST OF FIGURES

Number of Products under Development for Obesity, H2 2013
Products under Development for Obesity - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

COMPANIES MENTIONED

Boehringer Ingelheim GmbH
Shionogi & Co., Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Athersys, Inc.
GlaxoSmithKline plc
Isis Pharmaceuticals, Inc.
Merck & Co., Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Plexxikon Inc.
BioLineRx, Ltd.
Ipsen S.A.
Chong Kun Dang Pharmaceutical
Glenmark Pharmaceuticals Ltd.
GTx, Inc.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Norgine Limited
Pfizer Inc.
VIVUS, Inc.
Zydus Cadila Healthcare Limited
Genfit
Arrowhead Research Corporation
Ligand Pharmaceuticals Incorporated
Calzada Limited
PROLOR Biotech, Inc.
NeuroSearch A/S
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Unigene Laboratories, Inc.
Theratechnologies Inc.
Bukwang Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Phynova Group Ltd
Orexigen Therapeutics, Inc.
DiaMedica Inc.
NeuroVive Pharmaceutical AB
Digna Biotech, S.L.
Betagenon AB
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Upsher-Smith Laboratories, Inc.
Metabolex, Inc
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Spherix Incorporated
Ocera Therapeutics, Inc.
Aileron Therapeutics, Inc.
AngioChem Inc.
Global Health Ventures Inc.
Zafgen Inc.
Ambrx, Inc.
Braasch Biotech LLC
Zealand Pharma A/S
Indus Biotech Private Limited
Intarcia Therapeutics, Inc.
Thrasos, Inc.
Versartis, Inc.
Kainos Medicine, Inc.
Avaxia Biologics, Inc.
Omeros Corporation
Aegis Therapeutics, LLC
BRIDGE BIORESEARCH PLC
Globeimmune, Inc.
Targacept, Inc.
Molecular Design International, Inc.
N-Gene Research Laboratories, Inc.
PepTcell Limited
Galenea Corp.
Verva Pharmaceuticals Limited
Regulus Therapeutics Inc.
Esperion Therapeutics, Inc.
Domainex Ltd.
Lithera, Inc.
DiscoveryBiomed, Inc.
GlaxoSmithKline Inc.
Motif BioSciences, Inc.
Sirona Biochem Corp
Vicore Pharma AB
Reviva Pharmaceuticals Inc.
PharmaIN Corporation
Rhythm Pharmaceuticals
Obesity - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 107 pages
VIVUS, Inc. - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 69 pages
Athersys, Inc. - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 51 pages

Ask Your Question

Obesity - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: